Van ECK Associates Corp Purchases 276 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Van ECK Associates Corp raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 2.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 13,987 shares of the company’s stock after purchasing an additional 276 shares during the period. Van ECK Associates Corp’s holdings in IDEXX Laboratories were worth $6,116,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in IDXX. OFI Invest Asset Management bought a new stake in shares of IDEXX Laboratories in the third quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. acquired a new position in IDEXX Laboratories in the 3rd quarter valued at $26,000. Altshuler Shaham Ltd acquired a new position in IDEXX Laboratories in the 4th quarter valued at $26,000. Resurgent Financial Advisors LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $31,000. Finally, Whittier Trust Co. of Nevada Inc. grew its holdings in shares of IDEXX Laboratories by 108.6% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 73 shares of the company’s stock worth $32,000 after purchasing an additional 38 shares in the last quarter. Institutional investors own 86.85% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the transaction, the chief executive officer now directly owns 79,247 shares of the company’s stock, valued at approximately $45,377,624.67. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the transaction, the chief executive officer now owns 79,247 shares in the company, valued at approximately $45,377,624.67. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the transaction, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at approximately $3,851,815.44. The disclosure for this sale can be found here. Insiders have sold 62,288 shares of company stock valued at $34,600,528 in the last ninety days. 2.11% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of analyst reports. JPMorgan Chase & Co. boosted their price target on IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, December 20th. Piper Sandler lowered shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target on the stock. in a research report on Tuesday, January 30th. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research report on Friday, January 5th. Finally, Stifel Nicolaus reduced their target price on IDEXX Laboratories from $500.00 to $460.00 and set a “hold” rating on the stock in a report on Monday, October 30th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $591.50.

Read Our Latest Research Report on IDXX

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $572.21 on Friday. The firm’s fifty day moving average price is $540.92 and its two-hundred day moving average price is $491.38. The stock has a market cap of $47.52 billion, a PE ratio of 56.82, a PEG ratio of 3.16 and a beta of 1.25. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.57. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $579.68.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last released its quarterly earnings results on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The company had revenue of $901.60 million for the quarter, compared to analysts’ expectations of $891.88 million. During the same period in the previous year, the business posted $2.05 earnings per share. The business’s quarterly revenue was up 8.8% compared to the same quarter last year. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 11.13 EPS for the current fiscal year.

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Featured Articles

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.